Teva opts out of Rexahn partnership
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries decided not to exercise its option to develop the DNA and RNA synthesis inhibitor RX-3117 from Rexahn Pharmaceuticals for the treatment of solid tumors just before the small molecule drug was set to enter human clinical trials in the US.